Table 4 Relationship between CCN5 expression and clinicopathological features in 130 cases of advanced BC [n (%)]

PR

26.096

7.9 (3.4—18.2)

 < 0.001

 Positive

46

33 (71.74)

13 (28.26)

 Negative

74

18 (24.32)

56 (75.68)

HER-2

14.928

5.3 (2.2—12.9)

 < 0.001

 Positive

28

19 (67.86)

9 (32.14)

 Negative

112

32 (28.57)

80 (71.43)

Ki-67

45.489

0.1 (0—0.1)

 < 0.001

 High expression

84

15 (17.86)

69 (82.14)

 Low expression

46

36 (78.26)

10 (21.74)

P53

33.392

12.5 (4.8—32.4)

 < 0.001

 Wild type

35

28 (80.00)

7 (20.00)

 Mutant type

95

23 (24.21)

72 (75.89)

Age (years)

0.344

1.2 (0.6—2.5)

0.557

 < 54

52

22 (42.31)

30 (57.69)

 ≥ .5

78

29 (37.18)

49 (62.82)

Breast side

1.375

1.5 (0.7—3.1)

0.241

 Left breast

53

24 (45.28)

29 (54.72)

 Right breast

77

27 (35.06)

50 (64.94)

Tumour diameter (cm)

11.390

0.003

 < 2

8

6 (75.00)

2 (25.00)

1 (0.1—9.6)

 2–5

65

31 (47.69)

34 (52.31)

1 (0.5—2.0)

 > 5

57

14 (24.56)

43 (75.44)

1 (0.4—2.3)

Lymph node metastasis

7.225

0.3 (0.1—0.8)

0.007

 Yes

98

32 (32.65)

66 (67.35)

 No

32

19 (59.38)

13 (40.62)

Histological grade

3.983

2.4 (1.0—5.7)

0.046

 II

94

42 (44.68)

52 (55.32)

 III

36

9 (25.00)

27 (75.00)

Pathological molecular subtype

16.450

 < 0.001

 Luminal A

55

31 (56.36)

24 (43.64)

1 (0.5—2.1)

 Luminal B

26

11 (42.31)

15 (57.69)

1 (0.3—3.0)

 HER-2 overexpression

31

7 (22.58)

24 (77.42)

1 (0.3—3.3)

 Triple-negative

18

2 (11.11)

16 (88.89)

1 (0.1—8.0)

Clinical staging

37.787

 < 0.001

 IIB

14

10 (71.43)

4 (28.57)

1 (0.2—5.2)

 IIIA

25

17 (68.00)

8 (32.00)

1 (0.3—3.3)

 IIIB

12

9 (75.00)

3 (25.00)

1 (0.2—6.3)

 IIIC

79

15 (18.99)

64 (81.01)

1 (0.5—2.2)